Anebulo Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Anebulo Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($8.48M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($8.20M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($11.73M) | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | ($6.83M) | Sep 22, 2023 |
| FY2022 | Jun 30, 2021 | ($30.25M) | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | ($174.6K) | Sep 22, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($9.22M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($8.31M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($11.78M) | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | ($6.83M) | Sep 22, 2023 |
| FY2022 | Jun 30, 2021 | ($3.61M) | Sep 9, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.30M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $3.55M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $5.60M | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | $2.96M | Sep 22, 2023 |
| FY2022 | Jun 30, 2021 | $2.27M | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | $150.0K | Sep 22, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($6.35M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($8.09M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($9.68M) | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | ($5.44M) | Sep 22, 2023 |
| FY2022 | Jun 30, 2021 | ($4.87M) | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | ($150.8K) | Sep 22, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $12.15M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $4.07M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $11.67M | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | $15.58M | Sep 22, 2023 |
| FY2022 | Jun 30, 2021 | $21.65M | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | $3.03M | Sep 22, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $487.7K | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $260.6K | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $1.07M | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | $512.5K | Sep 22, 2023 |
| FY2022 | Jun 30, 2021 | $241.6K | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | $223.9K | Sep 22, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $11.66M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $3.81M | Sep 29, 2025 |
| FY2025 | Jun 30, 2023 | $10.60M | Sep 29, 2025 |
| FY2024 | Jun 30, 2022 | $15.07M | Sep 25, 2024 |
| FY2023 | Jun 30, 2021 | $21.41M | Sep 22, 2023 |
| FY2022 | Jun 30, 2020 | ($171.1K) | Sep 9, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($73.89M) | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | ($65.40M) | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | ($57.20M) | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | ($45.47M) | Sep 22, 2023 |
| FY2022 | Jun 30, 2021 | ($38.64M) | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | ($183.1K) | Sep 22, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $11.63M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | $3.09M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | $11.25M | Sep 25, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 22, 2023 |
| FY2022 | Jun 30, 2021 | (2) | Sep 9, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Sep 22, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 41.08M | Sep 29, 2025 |
| FY2025 | Jun 30, 2024 | 25.93M | Sep 29, 2025 |
| FY2024 | Jun 30, 2023 | 25.63M | Sep 25, 2024 |
| FY2023 | Jun 30, 2022 | 23.34M | Sep 22, 2023 |
| FY2022 | Jun 30, 2021 | 23.34M | Sep 9, 2022 |
| FY2021 | Jun 30, 2020 | 12.00M | Sep 22, 2021 |